Kymab: Old into new
Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the companys helm for good. Kymabs new old CEO is stepping down from his role as Chairman, however.
Chiswell was one of the co-founders of Cambridge Antibody Technology (CAT), where he also served as CEO from 1996 till 2002. Chiswell currently serves as chairman of Albireo Pharma, Swedish developer of treatments for gastrointestinal disease, and is a director of Austrias antibiotics specialist Nabriva Therapeutics. He is also a former chairman of the UK BioIndustry association (BIA). In 2006, he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium